601 related articles for article (PubMed ID: 27710160)
1. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
2. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
[TBL] [Abstract][Full Text] [Related]
5. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway.
Chen YF; Fan ZK; Gao X; Zhou F; Guo XF; Sinclair AJ; Li D
J Nutr Biochem; 2024 Jan; 123():109484. PubMed ID: 37866428
[TBL] [Abstract][Full Text] [Related]
6. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease.
Valenzuela R; Ortiz M; Hernández-Rodas MC; Echeverría F; Videla LA
Curr Med Chem; 2020; 27(31):5250-5272. PubMed ID: 30968772
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
8. Anti-steatotic effects of an n-3 LCPUFA and extra virgin olive oil mixture in the liver of mice subjected to high-fat diet.
Valenzuela R; Espinosa A; Llanos P; Hernandez-Rodas MC; Barrera C; Vergara D; Romero N; Pérez F; Ruz M; Videla LA
Food Funct; 2016 Jan; 7(1):140-50. PubMed ID: 26471014
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
10. Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE
Liu L; Hu Q; Wu H; Wang X; Gao C; Chen G; Yao P; Gong Z
Oxid Med Cell Longev; 2018; 2018():6256802. PubMed ID: 30538803
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
12. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Hodson L; Moyses HE; Calder PC; Byrne CD;
Hepatology; 2014 Oct; 60(4):1211-21. PubMed ID: 25043514
[TBL] [Abstract][Full Text] [Related]
13. Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.
Valenzuela R; Echeverria F; Ortiz M; Rincón-Cervera MÁ; Espinosa A; Hernandez-Rodas MC; Illesca P; Valenzuela A; Videla LA
Lipids Health Dis; 2017 Apr; 16(1):64. PubMed ID: 28395666
[TBL] [Abstract][Full Text] [Related]
14. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.
Depner CM; Philbrick KA; Jump DB
J Nutr; 2013 Mar; 143(3):315-23. PubMed ID: 23303872
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
Delarue J; Lallès JP
Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of various ratios of DHA/EPA supplementation on high-fat diet-induced liver damage in mice.
Shang T; Liu L; Zhou J; Zhang M; Hu Q; Fang M; Wu Y; Yao P; Gong Z
Lipids Health Dis; 2017 Mar; 16(1):65. PubMed ID: 28356106
[TBL] [Abstract][Full Text] [Related]
17. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
18. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Bone Turnover in Older Women.
Dong H; Hutchins-Wiese H; Kleppinger A; Annis K; Liva E; Lammi-Keefe C; Durham H; Feinn R; Kenny AM
Int J Vitam Nutr Res; 2014; 84(3-4):124-32. PubMed ID: 26098476
[TBL] [Abstract][Full Text] [Related]
19. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
[TBL] [Abstract][Full Text] [Related]
20. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial.
Manousopoulou A; Scorletti E; Smith DE; Teng J; Fotopoulos M; Roumeliotis TI; Clough GF; Calder PC; Byrne CD; Garbis SD
Clin Nutr; 2019 Aug; 38(4):1952-1955. PubMed ID: 30172659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
